Tumor DNA in blood during surgery may predict pancreatic cancer outcomes
NCT ID NCT06478056
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 40 patients with pancreatic cancer to measure circulating tumor DNA (ctDNA) in blood from a vein near the pancreas and in the arm, as well as in fluid from the belly, during surgery. The goal was to see if these DNA levels could help predict how the disease progresses. The study is complete and focused on understanding the disease better, not on testing a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better predict outcomes for pancreatic cancer patients by using tumor DNA levels during surgery.
- What could go wrong
- This is a small, completed observational study, not a treatment trial. The findings may not lead to immediate clinical changes or apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital, Rouen
Rouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?
- Can a pill rouse the immune system against pancreatic cancer?